Pfizer, BioNTech lose UK appeal in Moderna patent case
Last year, the High Court ruled that one of Moderna's patents relating to the messenger RNA (mRNA) technology which underpinned its Covid-19 vaccine was valid and that Pfizer and BioNTech's Comirnaty vaccine had infringed it, meaning Moderna is entitled to damages in relation to sales after March 2022.
The High Court also ruled that the other Moderna patent under challenge in the case was invalid. Moderna was refused permission to appeal against that decision.
But Pfizer and BioNTech were granted permission to appeal in an attempt to try and invalidate Moderna's second patent and appealed earlier this month, arguing Moderna's developments of mRNA technology were obvious developments of previous work, rendering the patent invalid.
Judge Richard Arnold, however, rejected Pfizer and BioNTech's appeal.
Pfizer and BioNTech said in a joint statement that the decision 'does not change our unwavering stance that this patent is invalid' and the companies will seek to appeal.
'This decision has no immediate impact on Pfizer and BioNTech or Comirnaty,' the companies added.
Moderna did not immediately respond to a request for comment.
Friday's decision in the latest ruling in the legal dispute between the two sides over their competing vaccines, which helped save millions of lives during the pandemic.
The companies have also been involved in proceedings in Germany – where a court ruled in Moderna's favour in March – the United States Patent Office, which held that two Moderna Covid-19 vaccine patents were invalid, and elsewhere. - Reuters
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
4 hours ago
- The Star
Trump fires US labor official over data and gets earlier than expected chance to reshape Fed
WASHINGTON/NEW YORK (Reuters) -President Donald Trump on Friday fired a top Labor Department official on the heels of a market-shocking weak scorecard of the U.S. job market, accusing her without evidence of manipulating the figures and adding to already growing concerns about the quality of economic data published by the federal government. In a second surprise economic policy development, the door for Trump to make an imprint on a Federal Reserve with which he clashes almost daily for not lowering interest rates opened much earlier than anticipated when Fed Governor Adriana Kugler unexpectedly announced her resignation on Friday afternoon. The two developments further rattled a stock market already reeling from his latest barrage of tariff announcements and the weak jobs data. The benchmark S&P 500 Index sank 1.6% in its largest daily drop in more than two months. Trump accused Erika McEntarfer, appointed by former President Joe Biden, of faking the jobs numbers. There is no evidence to back Trump's claims of data manipulation by the Bureau of Labor Statistics, the statistical agency that compiles the closely watched employment report as well as consumer and producer price data. A representative for the BLS did not respond to a request for comment. Friday began with BLS reporting the U.S. economy created only 73,000 jobs in July, but more stunning were net downward revisions showing 258,000 fewer jobs had been created in May and June than previously reported. "We need accurate Jobs Numbers. I have directed my Team to fire this Biden Political Appointee, IMMEDIATELY. She will be replaced with someone much more competent and qualified," Trump said in a post on Truth Social. DATA CONCERNS A Trump administration official who requested anonymity said that while all economic data is noisy, the White House has been dissatisfied with how large the revisions have been in the recent data and issues with lower survey responses. The problem started during COVID and has not been addressed in the years since. "There are these underlying problems that have been festering here for years now that have not been rectified," the person said. "The markets and companies and the government need accurate data, and like, we just weren't getting that," the official said. The BLS has already reduced the sample collection for consumer price data as well as the producer price report, citing resource constraints. The government surveys about 121,000 businesses and government agencies, representing approximately 631,000 individual worksites for the employment report. The response rate has declined from 80.3% in October 2020 to about 67.1% in July, BLS data shows. A Reuters poll last month found 89 of 100 top policy experts had at least some worries about the quality of U.S. economic data, with most also concerned that authorities are not addressing the issue urgently enough. In addition to the concerns over job market data, headcount reductions at BLS have resulted in it scaling back the scope of data collection for the Consumer Price Index, one of the most important gauges of U.S. inflation, watched by investors and policymakers worldwide. Trump's move fed into concerns that politics may influence data collection and publication. "Politicizing economic statistics is a self-defeating act," said Michael Madowitz, principal economist at the Roosevelt Institute's Roosevelt Forward. "Credibility is far easier to lose than rebuild, and the credibility of America's economic data is the foundation on which we've built the strongest economy in the world. Blinding the public about the state of the economy has a long track record, and it never ends well." FED CHANGE SOONER THAN EXPECTED Meanwhile, Kugler's surprise decision to leave the Fed at the end of next week presents Trump an earlier-than-expected opportunity to install a potential successor to Fed Chair Jerome Powell on the central bank's Board of Governors. Trump has threatened to fire Powell repeatedly because the Fed chief has overseen a policymaking body that has not cut interest rates as Trump has demanded. Powell's term expires next May, although he could remain on the Fed board until January 31, 2028, if he chooses. Trump will now get to select a Fed governor to replace Kugler and finish out her term, which expires on January 31, 2026. A governor filling an unexpired term may then be reappointed to a full 14-year term. Some speculation has centered on the idea Trump might pick a potential future chair to fill that slot as a holding place. Leading candidates for the next Fed chair include Trump economic adviser Kevin Hassett, Treasury Secretary Scott Bessent, former Fed Governor Kevin Warsh and Fed Governor Chris Waller, a Trump appointee who this week dissented with the central bank's decision to keep rates on hold, saying he preferred to start lowering them now. Trump, as he was leaving the White House to spend the weekend at his Bedminster, New Jersey, estate, said he was happy to have the open slot to fill. "I would not read any political motivation into what [Kugler is] doing, although the consequence of what she's doing is she's calling Trump's bluff,"said Derek Tang, an analyst at LH Meyer, a research firm. "She's putting the ball in his court and saying, look, you're putting so much pressure on the Fed, and you want some control over nominees, well, here's a slot." (Additional reporting by Jasper Ward and Trevor Hunnicutt; Writing by Daniel Burns; Editing by Chris Reese and Nia Williams and Anna Driver)
Sinar Daily
5 hours ago
- Sinar Daily
Who makes laundry smell nice? Meet the professional 'noses'
HOLZMINDEN - In the laboratories of German fragrance and flavours giant Symrise, a citrus scent clings to the lab coats of trainees, "noses" who are learning the art of making things smell good. These busy heroes of the world of smells and aromas shape the connection millions of consumers have with everyday items. While at high-end perfume labels, olfactory artists create scents for luxury body sprays, Symrise's experts work on everyday products that might range from mint-flavoured toothpaste to barbeque chips. Smell, a powerful sense that can trigger emotions and memories, and aroma often decide which food or beverage, cleaning or personal hygiene product ends up in the shopping cart. At Symrise's headquarters in Holzminden, a quiet town south of Hanover, each day at the company's in-house perfumery school begins the same way: sniffing out scents from dozens of tiny bottles while blindfolded. "It's just like tuning a musical instrument before you play," said Alicia De Benito Cassado, a 32-year-old former professional pianist from Spain. Her career switch into scent development was a natural step: she made her own perfumes as a teenager to match the poetry and music that she wrote. "For me, not everything has to smell good," she said. "The horror of smell also helps us discover ourselves." But commercial clients demand something different, De Benito Cassado added. "In the end, we need to create scents that are strong, beautiful, powerful and affordable." - Professional sniffers - Being a "nose" is a full-time job and comes with a three-year training programme. The smell of a fabric softener can be composed of 80 compounds, far more than in a premium body perfume and the best noses can make out over 1,000 different odours while blindfolded. Junior perfumers (L-R) Attiya Setai, Shangyun Lyu and Alicia de Benito Cassado hold smell strips which are used to evaluate fragrances in a mixing room at the Symrise company, where perfume oil formulas are developed, in Holzminden, central Germany. Photo by Michael Matthey/AFP Shangyun Lyu, 31, came from China to study at the school and says that a professional sniffer can get by with knowing about 500 scents. Being able to break down odours into their chemical components is key. "As a kid, I just smelled jasmine or gardenia as flowers," he said. "Now, I recognise the chemicals: it's a blend of many elements." Students weigh ingredients down to the milligramme, mix, smell and start over, often by replicating existing smells to understand their structure and then innovate from there. "When developing perfume, it is very important that several people smell it," said 56-year-old master perfumer Marc vom Ende, head of the school. "We all perceive smell differently." - 'Nose has the final say' - Pleasant smells cannot come at any cost and the rules of the game change over time. Lilial, a chemical once prized for its floral and sweet Lily-of-the-Valley notes, has been banned in the European Union since 2022 over fears it can cause skin irritation and damage the reproductive system. Fragrances applied directly to the body have stricter regulations than detergents, said 27-year-old South African trainee Attiya Setai. "We're more restricted in raw materials and must replace banned ingredients with new compliant ones," she said. Tastes also vary across global markets, with Shangyun pointing to the example of Chinese shampoos that sell well with a young clientele there but would struggle in Europe. "Something old-fashioned in one country can be new elsewhere," he said. Cost also enters the equation. Symrise extracts aromatic compounds from wood resin, a by-product of the paper industry, in a move "that makes both economic and environmental sense", said vom Ende. It is hard to be a nose. About 500 perfumers work in the industry and 80 of them at Symrise, which has a workforce of 13,000. The company markets about 30,000 products to clients ranging from confectioners to pet food manufacturers and suncream makers. Symrise's competitors include DSM-Firmenich, headquartered in both Switzerland and the Netherlands, as well as Givaudan, another Swiss firm. Artificial intelligence increasingly plays a role, with computer programmes predicting which fragrances will hit the mark. Still, the machines cannot -- yet -- smell, even if they can understand speech and read text. "We're supported by AI," vom Ende said. "But the nose has the final say". - AFP
New Straits Times
8 hours ago
- New Straits Times
Pfizer, BioNTech lose UK appeal to Moderna in Covid-19 vaccine patent fight
LONDON: US pharmaceutical giant Pfizer and German firm BioNTech lost Friday a court appeal in the latest step of a multi-million pound battle against US rival Moderna over the Covid-19 vaccine. The Appeals Court in London upheld an earlier UK court decision in the long-running battle between the global pharma firms. It found that one of the European patents held by Moderna was invalid, but that a second one had been broken by Pfizer and its German partner BioNTech. "The judge made no error of law or principle" in the ruling handed down in July 2024, the Appeal Court judges wrote Friday, dismissing the appeal brought by the two companies. Pfizer quickly said it will appeal Friday's ruling to Britain's Supreme Court. "Today's UK Court of Appeal's decision does not change our unwavering stance that this patent is invalid," Pfizer said in a statement. "This decision has no immediate impact on Pfizer and BioNTech." Pfizer and BioNTech had argued that both the patents cited by Moderna were invalid, and neither had been infringed. Friday's decision could have wide implications for other cases involving the huge pharma companies in the United States, Germany, Belgium, the Netherlands and Ireland. Moderna said in a statement it was pleased with Friday's ruling and would "continue to pursue and enforce its patent rights globally to protect its innovative mRNA technology." A UK court was told last year the firms had spent £19 million (US$25 million) fighting their legal battles. In 2020, Pfizer and BioNTech's vaccine became the first ever mRNA vaccine approved for widespread use, and was swiftly deployed to combat the Covid pandemic. Scientists believe mRNA vaccines, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells, could be a game-changer against many diseases. Traditional vaccines contain some form of the dead or inactivated target virus. Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than traditional vaccines. In March, a German court in Duesseldorf also found Pfizer and BioNTech had violated a Moderna patent filed between 2010 to 2016 to make their vaccines. It ordered they must provide estimates of how much they had profited from breaking the patent as well as provide "appropriate compensation."--AFP
